Mandate

Vinge advises Astrego Diagnostics AB in conjunction with capital procurement

January 29, 2020 M&A

Vinge has advised Astrego Diagnostics AB in connection with the investment in the company by the Japanese company Sysmex Corporation, which has acquired approximately 25% of the shares in the company.

Astrego develops a ground‑breaking technology for characterization of antibiotic‑sensitivity. The first product gives doctors a patient specific diagnostic tool for urinary infections.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg and Viktoria Owetz Leyva.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025